Based on initial laboratory tests, the British company Glaxo Kline announced that its anti-Covid-19 drug appears to be effective against the new mutant Omicron.

The British pharmaceutical company hopes to complete tests by the end of 2021, to confirm whether the drug - which relies on antibodies - is effective against all the various mutations seen with the new mutant.

The Declaration is one of the first indications that some of the current anti-COVID-19 treatments will at least retain their effectiveness against the emerging mutant strain.

The pharmaceutical company Regeneron had warned that the antibody combination seemed to lose its effectiveness against omicron.

While it is the only option available to mild to moderate patients who have not yet been hospitalized, it remains

Antibody-based treatments are one of a few drugs that could mitigate the worst effects of CoVID-19.

These drugs are copies made in the laboratory of antibodies facing the virus that the immune system uses to defend the body against infection.

It should be noted that the United States Government purchased millions of doses of antibody treatments manufactured by Glaxo Clayne, Regeneron and Eli Lilly, and distributed them to states throughout the country.

Glaxo Kline, which relies on antibodies, has also been approved in Britain, Canada, Australia and Japan.